Raymond James Downgrades INmune Bio Inc. (INMB) to Market Perform

Go back to Raymond James Downgrades INmune Bio Inc. (INMB) to Market Perform

BTIG Downgrades INmune Bio Inc. (INMB) to Neutral

June 30, 2025 4:37 PM EDT

BTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.

The analyst comments "A solid MAYBE but with no clear way forward and management talking about moving to other programs - so NEUTRAL makes sense. The size of the AD opportunity hasn't changed, so the current stock price (about $2 all day) equates to a probability of success in AD of 0% with all revenues coming from MDD. Our two biggest worries going into this readout (preview HERE) were: 1) the modest enrichment in the MINDFul trial population, based on one (of four)... More